Research map: Baseline Inflammatory Burden Index Predicts Primary Resistance to Combinations of ICIs With Chemotherapy in Patients With HER-2-Negative Advanced Gastric Cancer

Back to the article

Papers in this map

  1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries · Hyuna Sung · 2021 · 114646 citations · Cited by this paper
  2. Combined Inflammatory Burden Index and hand grip strength for prognostic assessment in gastric cancer patients: a multicenter cohort study · Fuquan Yang · 2026 · Cites this paper
  3. Real-World Evidence for Expanding the Criteria for Endoscopic Resection in Submucosal Gastric Cancer: The Role of Invasion Width · 2026 · Related
  4. Inflammation and Cancer: Triggers, Mechanisms, and Consequences · Florian R. Greten · 2019 · 3885 citations · Cited by this paper
  5. The CALLY Index for Unresectable or Recurrent Gastric Cancer Treated With Nivolumab: A Multicenter Retrospective Study · Kenji Takeshita · 2026 · Cites this paper
  6. Endoscopic Features of Background Gastritis Associated With Remnant Gastric Cancer: A Multicenter Retrospective Study · 2026 · Related
  7. Characteristics and Significance of the Pre-metastatic Niche · Yang Liu · 2016 · 1392 citations · Cited by this paper
  8. Targeting RPRD1B overcomes chemoresistance in gastric cancer by suppressing the TOPBP1-mediated DNA damage repair pathway · Jian Sheng · 2026 · Cites this paper
  9. Nutritional Counseling for Patients With Gastric Cancer After Subtotal Gastrectomy: A Randomized Clinical Trial · 2025 · Related
  10. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination · Jiali Yu · 2021 · 1030 citations · Cited by this paper
  11. Korean Gastric Cancer Association-Led Nationwide Survey on Surgically Treated Gastric Cancers in 2023 · 2025 · Related
  12. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial · Sun Young Rha · 2023 · 698 citations · Cited by this paper
  13. A Critical Review of the Impact of Different Types of Complications on Long-Term Survival After Total Gastrectomy for Gastric Cancer: Addressing Methodological Gaps and Clinical Implications · 2025 · Related
  14. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy · Christopher Tay · 2023 · 582 citations · Cited by this paper
  15. Temporal Ambiguity Limits Interpretation of Endoscopic “Risk Markers” for Remnant Gastric Cancer: Comment on the Study by Ohashi et al. · 2026 · Related
  16. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials · Joseph Chao · 2021 · 463 citations · Cited by this paper
  17. Nationwide Survey on Endoscopic Submucosal Dissection for Early Gastric Cancer in Korea: Results From the Korean College of Helicobacter and Upper Gastrointestinal Research (KCHUGR) 2023 Survey · 2026 · Related
  18. Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer · Jianming Xu · 2023 · 406 citations · Cited by this paper
  19. Rethinking Neoadjuvant Therapy: A Critical Evaluation of Exclusion Criteria in Gastric Cancer Surgery Studies · 2025 · Related
  20. Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab · Jingjing Liu · 2019 · 387 citations · Cited by this paper
  21. Recent Advances in Endoscopic Submucosal Dissection for Gastric Cancer: Focusing on Expanded Indications and Technological Innovations · 2025 · Related
  22. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations · Curtis H. Kugel · 2018 · 371 citations · Cited by this paper
  23. Tumor-associated neutrophils and neutrophil-targeted cancer therapies · Haiying Que · 2022 · 344 citations · Cited by this paper
  24. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial · Miao‐Zhen Qiu · 2024 · 291 citations · Cited by this paper
  25. Inflammation: the incubator of the tumor microenvironment · Dominic Denk · 2022 · 281 citations · Cited by this paper
  26. Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability–High Gastric Cancer · Minsuk Kwon · 2021 · 252 citations · Cited by this paper
  27. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial · Yelena Yuriy Janjigian · 2024 · 249 citations · Cited by this paper
  28. Microsatellite instability in Gastric Cancer: Between lights and shadows · Elisabetta Puliga · 2021 · 215 citations · Cited by this paper
  29. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials · Filippo Pietrantonio · 2021 · 200 citations · Cited by this paper
  30. C-reactive protein and cancer risk: a pan-cancer study of prospective cohort and Mendelian randomization analysis · Meng Zhu · 2022 · 192 citations · Cited by this paper
  31. Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer · Qiaoqi Sui · 2022 · 166 citations · Cited by this paper
  32. Inflammatory burden as a prognostic biomarker for cancer · Hailun Xie · 2022 · 165 citations · Cited by this paper
  33. Development and validation of an immune-related gene pairs signature in colorectal cancer · Jianping Wu · 2019 · 133 citations · Cited by this paper
  34. Pharmacological principles of intraperitoneal and bidirectional chemotherapy · Eelco de Bree · 2017 · 129 citations · Cited by this paper
  35. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers · Giovanni Fucà · 2022 · 124 citations · Cited by this paper
  36. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non‐small cell lung cancer · Ilaria Alborelli · 2019 · 117 citations · Cited by this paper
  37. Positive Status of Epstein-Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study · Tong Xie · 2020 · 107 citations · Cited by this paper
  38. Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: A retrospective study · Dan Nie · 2018 · 102 citations · Cited by this paper
  39. Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study · Keun‐Wook Lee · 2022 · 90 citations · Cited by this paper

Source: OpenAlex (CC0)